For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
The Re-Militarization of Germany
Inflation Is Way Down. Is It by Design or Just Luck?
The Sunday Read: ‘The High-Risk Feat of Bringing ‘American Born Chinese’ to TV’
The Kids Take the Climate Change Fight to Court
How Saudi Arabia Took on Pro Golf — and Won
Arraigned, Again: Trump’s Federal Court Hearing in Miami
A Forced Reckoning in the Restaurant Industry
Nuclear Secrets and Taped Conversations: A Look at the Evidence Against Trump.
The Sunday Read: ‘The Most Dangerous Person in the World Is Randi Weingarten’
Special Episode: A Second Trump Indictment
There’s No Escaping Wildfire Smoke
A Guide to the Suddenly Crowded Republican Primary
Turned Away and Left at Sea
The Fight Over Phonics
The New Afghanistan, Through the Eyes of Three Women
Special Episode: A Crash Course in Dembow, a Misunderstood Pantry Staple and Simple Tips to Keep Calm and Carry On
America’s Big City Brain Drain
How the G.O.P. Picked Trans Kids as a Rallying Cry
Republicans Impeach One of Their Own
The Godfather of A.I. Has Some Regrets
Create your
podcast in
minutes
It is Free
Up First from NPR
Consider This from NPR
The World
The Ezra Klein Show
Today in Focus